{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:00:39Z","timestamp":1785348039313,"version":"3.55.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isavuconazole (ISCZ) is an azole antifungal with a low risk of QTc prolongation and no requirement for renal dose adjustment. However, real-world data in Asian patients remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 45 patients who received ISCZ between April 2023 and March 2025. Laboratory parameters and QTc values (QTcB\/QTcF) were extracted from medical records. Longitudinal changes were assessed using linear mixed-effects models. In patients receiving arsenic trioxide (ATO), QTc trajectories were compared among ATO alone, ATO with ISCZ (ATO-ISCZ), and ATO with other antifungals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Grade \u22652 elevations in AST and ALT occurred in 11.1% and 13.3% of patients, respectively, and were transient. No significant deterioration in laboratory parameters was observed. In the ATO subgroup, QTc values in the ATO-ISCZ group were lower than those in the ATO group from Day 30, with the largest difference at Day 70 (\u221245.5 ms for QTcB and \u221242.3 ms for QTcF; both p\u2009&lt;\u20090.001). The ATO\u2013other antifungals group showed similar trends to the ATO group. No clinically significant cardiac events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ISCZ showed a favorable safety profile in Japanese patients with hematologic malignancies and may be a safe option during QT-prolonging therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354816","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:31:13Z","timestamp":1785346273000},"page":"e0354816","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal changes in laboratory parameters and QTc during isavuconazole therapy in Japanese patients with hematologic malignancies"],"prefix":"10.1371","volume":"21","author":[{"given":"Koichi","family":"Ohata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-1525","authenticated-orcid":true,"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7577-0382","authenticated-orcid":true,"given":"Yuto","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1453-4360","authenticated-orcid":true,"given":"Mio","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-7777","authenticated-orcid":true,"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-9918","authenticated-orcid":true,"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"6","key":"pone.0354816.ref001","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"JP Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0354816.ref002","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"L Pagano","year":"2025","journal-title":"Leukemia"},{"issue":"12","key":"pone.0354816.ref003","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"OA Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10020","key":"pone.0354816.ref004","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"JA Maertens","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"pone.0354816.ref005","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"FM Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0354816.ref006","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40262-018-0673-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"57","author":"MW McCarthy","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"pone.0354816.ref007","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"A Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"pone.0354816.ref008","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent","volume":"61","author":"MH Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0354816.ref009","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent","volume":"35","author":"JM Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"3","key":"pone.0354816.ref010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","article-title":"Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism","volume":"51","author":"J Schulz","year":"2019","journal-title":"Drug Metab Rev"},{"issue":"4","key":"pone.0354816.ref011","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12886","article-title":"Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients","volume":"20","author":"O Imataki","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"pone.0354816.ref012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ijpp.12302","article-title":"Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections","volume":"25","author":"D Murrell","year":"2017","journal-title":"Int J Pharm Pract"},{"key":"pone.0354816.ref013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"AH Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"pone.0354816.ref014","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: In vitro and in vivo effects on cardiac repolarization","volume":"101","author":"J Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pone.0354816.ref015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"SC Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"pone.0354816.ref016","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12712","article-title":"Use of isavuconazole in a patient with voriconazole-induced QTc prolongation","volume":"19","author":"TP Trang","year":"2017","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"pone.0354816.ref017","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-133-11-200012050-00012","article-title":"Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia","volume":"133","author":"K Ohnishi","year":"2000","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0354816.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00221-2","article-title":"The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview","volume":"23","author":"EL Giraud","year":"2022","journal-title":"Lancet Oncol"},{"issue":"19","key":"pone.0354816.ref019","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"JT Barbey","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0354816.ref020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jiac.2022.10.010","article-title":"Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan","volume":"29","author":"S Kohno","year":"2023","journal-title":"J Infect Chemother"},{"key":"pone.0354816.ref021","article-title":"Real-World, Multicenter Case Series of Patients Treated with Isavuconazole for Invasive Fungal Disease in China","volume":"11","author":"L Wu","year":"2023","journal-title":"Microorganisms"},{"key":"pone.0354816.ref022","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2147\/IDR.S505709","article-title":"Safety and Effectiveness of Isavuconazole Treatment for Invasive Fungal Infections in Chinese Patients with Haematologic Diseases: A Case Series","volume":"18","author":"P Luo","year":"2025","journal-title":"Infect Drug Resist"},{"issue":"3","key":"pone.0354816.ref023","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Y Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"pone.0354816.ref024","volume-title":"R: A language and environment for statistical computing","author":"CT R","year":"2024"},{"issue":"10","key":"pone.0354816.ref025","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s12012-025-10051-1","article-title":"Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database","volume":"25","author":"L Chen","year":"2025","journal-title":"Cardiovasc Toxicol"},{"issue":"6","key":"pone.0354816.ref026","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"R Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0354816.ref027","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/myc.13622","article-title":"A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections","volume":"66","author":"H Kato","year":"2023","journal-title":"Mycoses"},{"issue":"9","key":"pone.0354816.ref028","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry","volume":"10","author":"MH Nguyen","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"pone.0354816.ref029","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Y Bogler","year":"2021","journal-title":"Med Mycol"},{"issue":"3","key":"pone.0354816.ref030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/myc.12885","article-title":"Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events","volume":"62","author":"F Bongomin","year":"2019","journal-title":"Mycoses"},{"key":"pone.0354816.ref031","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","author":"MM Chau","year":"2021","journal-title":"Intern Med J"},{"issue":"7","key":"pone.0354816.ref032","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/jpm15070274","article-title":"Major Allele Frequencies in CYP2C9 and CYP2C19 in Asian and European Populations: A Case Study to Disaggregate Data Among Large Racial Categories","volume":"15","author":"H-EV Nieh","year":"2025","journal-title":"J Pers Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:31:22Z","timestamp":1785346282000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354816"}},"subtitle":[],"editor":[{"given":"Felix","family":"Bongomin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354816","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}